RT Journal Article
SR Electronic
T1 Propofol sedation in lung transplant recipients: the impact of cystic fibrosis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA2198
DO 10.1183/13993003.congress-2021.PA2198
VO 58
IS suppl 65
A1 Marco Damin
A1 Davide Biondini
A1 Mariaenrica Tine
A1 Elisabetta Cocconcelli
A1 Michele Rizzo
A1 Giulia Andreotti
A1 Nicola Malacchini
A1 Simone Petrarulo
A1 Federico Lionello
A1 Manuel G. Cosio
A1 Marina Saetta
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA2198.abstract
AB Introduction: Surveillance bronchoscopy (SB) represents an important diagnostic tool in the follow-up and management of lung transplant (LTx) complications. Propofol, a short acting non‐opioid sedative–hypnotic, provides safe and effective sedation during bronchoscopy. However, the sedation requirements in transplanted patients and specially in cystic fibrosis (CF) have not been well determined.Aim: To evaluate whether CF recipients may require different amounts of intravenous propofol during SB compared to non-CF.Methods: A single-centre retrospective study of all transplanted patients undergoing SB from January to December 2019 was performed. Propofol was the only drug administered to achieve deep sedation. CF and non-CF recipients were compared regarding age, BMI and mean propofol dose.Results: 121 patients, 51 CF and 70 non-CF, were evaluated. Non-CF included patients with idiopathic pulmonary fibrosis (IPF, n=23), Chronic Obstructive Pulmonary Disease (COPD, n=17) and other diseases (n=30). CF patients were younger (33±11 vs 55±9; p<0.0001) and had lower BMI (23±3 vs 25±4; p=0.003) than non-CF. Moreover, the mean propofol dose per weight required in CF was significantly higher than non-CF (6±2 vs 3±1 mg/kg; p<0.0001), even when considered as single diseases (IPF p<0.0001, COPD p=0.0001 and OD p<0.0001). Multiple linear regression analysis including BMI, age and years from transplantation showed that having CF independently predicts propofol dosage (β=0.3; p=0.01).Conclusions: CF recipients required higher dosages of propofol during surveillance bronchoscopy compared to non-CF. The known enhanced clearances of many drugs, to which propofol should be added, very likely explain our results.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2198.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).